Find An Allergist / Immunologist | Pollen Levels | Journal of Allergy and Clinical Immunology | Annual Meeting   Contact    About AAAAI    Search
Patients & Consumers Conditions En Español Find an Allergist / Immunologist Just for Kids New Research Parent Resources Pollen Levels Publications Real Life Stories Request a Speaker School Tools Seniors The Virtual Allergist™ Treatments Search by Condition (A-Z) Search by Topic Allergy & Asthma Issues Educational Brochures Elements of Allergy and Asthma Order Public Education Materials Washington Post Supplement Allergy Shots Drug Guide Sublingual Immunotherapy (SLIT)		SELECTED ARTICLES FROM THE RECENT LITERATURE 2008 7/9/2008 Omalizumab Compared to Suplatast Tosilate for Treatment of Seasonal Allergic Rhinitis Summary Suplatast is a T-helper 2 (Th2) cytokine inhibitor. In this study, which was a randomized, double-blind, double-dummy evaluation in 308 Japanese patients with a history of moderate to severe seasonal allergic rhinitis, suplatast was compared to omalizumab The omalizumab group demonstrated significantly lower mean daily nasal severity scores, reduced medication requirements, and a reduced proportion of days when rescue medication was needed. The authors concluded that omalizumab showed significantly greater improvements than suplatast for the treatment of seasonal allergic rhinitis. Reference Nagakura T, et al. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clinical and Experimental Allergy, 38:329-337, 2007.   Back
		© 1996-2010 · All Rights Reserved · American Academy of Allergy Asthma & Immunology Disclaimers and Contact Information · Site Map